MIXED AMINO ACID/MINERAL COMPOUNDS HAVING IMPROVED SOLUBILITY
    2.
    发明申请
    MIXED AMINO ACID/MINERAL COMPOUNDS HAVING IMPROVED SOLUBILITY 有权
    具有改善溶解性的混合氨基酸/矿物化合物

    公开(公告)号:US20070172551A1

    公开(公告)日:2007-07-26

    申请号:US11623476

    申请日:2007-01-16

    IPC分类号: A23L1/30

    摘要: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.

    摘要翻译: 混合的氨基酸/矿物化合物可包括与中心矿物原子结合的至少两个氨基酸。 可以调整氨基酸的组合以提供矿物质的改善的溶解度,吸收和/或生物利用度。 任选地,有机酸可以与矿物结合或与螯合物结合,以进一步改善溶解度,吸收和/或生物利用度。 包括一种或多种混合氨基酸/矿物化合物的组合物可以包括在用于矿物可以治疗和/或预防病症或症状的适应症的治疗方案中。

    COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS
    4.
    发明申请
    COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS 审中-公开
    用于局部治疗混合性阴道感染的组合物

    公开(公告)号:US20110251141A1

    公开(公告)日:2011-10-13

    申请号:US13164326

    申请日:2011-06-20

    摘要: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

    摘要翻译: 药物组合物包含(a)抗菌有效量的抗菌剂,例如包括克林霉素或其药学上可接受的盐或酯; 和(b)抗真菌有效量的抗真菌剂,例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用,并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。

    COMPOSITIONS AND THERAPEUTIC METHODS OF USE
    5.
    发明申请
    COMPOSITIONS AND THERAPEUTIC METHODS OF USE 审中-公开
    组合物和治疗方法的使用

    公开(公告)号:US20080003262A1

    公开(公告)日:2008-01-03

    申请号:US11769901

    申请日:2007-06-28

    CPC分类号: A61K31/7056 A61K9/0034

    摘要: A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.5% to about 4% by weight; and (b) a phospholipid or non-ionic ester surfactant; wherein the composition is a vaginal cream having at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface.

    摘要翻译: 用于治疗非传染性炎症性外阴阴道炎的方法包括向外阴阴道表面施用药物组合物,其包含每单位剂量组合物约125mg至约400mg量的克林霉素; 其中所述组合物对外阴阴道表面具有生物粘附性,并且当将组合物施用于外阴阴道表面时,克林霉素在约3小时至约14天的时间内释放。 相关方法包括向外阴阴道表面施用包含克林霉素或其药学上可接受的盐或酯的药物组合物,其中所述组合物具有至少一个非脂质内相和至少一个与外阴阴道表面生物粘附的脂质外相。 药物组合物包含(a)克林霉素或其药学上可接受的盐或其克林霉素当量为约2.5重量%至约4重量%的盐或酯; 和(b)磷脂或非离子酯表面活性剂; 其中所述组合物是具有至少一个非脂质内相和至少一个与阴道粘膜表面生物粘附的脂质外部相的阴道霜。

    COMPOSITION AND METHOD OF USE THEREOF
    6.
    发明申请
    COMPOSITION AND METHOD OF USE THEREOF 审中-公开
    组合物及其使用方法

    公开(公告)号:US20070224226A1

    公开(公告)日:2007-09-27

    申请号:US11617180

    申请日:2006-12-28

    IPC分类号: A61K9/00 A61K31/4172

    摘要: A pharmaceutical composition comprises (a) metronidazole in an antibacterially effective amount; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

    摘要翻译: 药物组合物包含(a)抗菌活性量的甲硝唑; 和(b)抗真菌有效量的抗真菌剂,例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用,并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。

    Cardiovascular compositions
    8.
    发明申请
    Cardiovascular compositions 审中-公开
    心血管成分

    公开(公告)号:US20060135610A1

    公开(公告)日:2006-06-22

    申请号:US11021282

    申请日:2004-12-22

    IPC分类号: A61K31/202 A61K31/225

    摘要: Compositions that promote and/or maintain cardiovascular health through the treatment of one or more cardiovascular diseases are provided. Also provided are methods for using compositions that promote and/or maintain cardiovascular health through the prevention, stabilization, reversal and/or treatment of coronary artery disease and/or cerebrovascular disease. Such compositions may be used independently to promote and/or maintain cardiovascular health or used in combination with one or more other compositions used in the treatment of various other disease states common to aging and/or a health deteriorating condition.

    摘要翻译: 提供通过治疗一种或多种心血管疾病促进和/或维持心血管健康的组合物。 还提供了通过预防,稳定,逆转和/或治疗冠状动脉疾病和/或脑血管疾病来使用促进和/或维持心血管健康的组合物的方法。 这样的组合物可以独立地用于促进和/或维持心血管健康,或与用于治疗衰老和/或健康恶化状况共同的各种其它疾病状态的一种或多种其它组合物组合使用。

    COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS
    9.
    发明申请
    COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS 审中-公开
    用于局部治疗混合性阴道感染的组合物

    公开(公告)号:US20130172279A1

    公开(公告)日:2013-07-04

    申请号:US13557527

    申请日:2012-07-25

    摘要: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.

    摘要翻译: 药物组合物包含(a)抗菌有效量的抗菌剂,例如包括克林霉素或其药学上可接受的盐或酯; 和(b)抗真菌有效量的抗真菌剂,例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用,并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。

    SUSTAINED-RELEASE COMPOSITION AND METHOD OF USE THEREOF
    10.
    发明申请
    SUSTAINED-RELEASE COMPOSITION AND METHOD OF USE THEREOF 审中-公开
    持续释放组合物及其使用方法

    公开(公告)号:US20080139655A1

    公开(公告)日:2008-06-12

    申请号:US11850063

    申请日:2007-09-05

    IPC分类号: A61K31/195 A61P25/28

    摘要: A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.

    摘要翻译: 提供包含左旋多巴的药物组合物,其以约6至约24小时的剂量间隔以约100至约500mg的单位剂量的左旋多巴施用时,显示足够长的释放期和足够长的停留时间 上消化道提供受试者血浆中左旋多巴的谷浓度,其不低于在受试者中观察到不良运动效应的最低阈值浓度。 还提供了治疗受试者中帕金森病的方法,其包括以约3至约24小时的剂量间隔以约50至约1000mg的单位剂量的左旋多巴口服施用该组合物。